The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $360.67

Today's change+6.97 +1.97%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $360.67

Today's change+6.97 +1.97%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Biogen Idec Inc Hits New 52-week High

Biogen Idec Inc closed up sharply Friday, rallying (U.S.)$6.97 or 1.97% to (U.S.)$360.67 and setting a new 52-week high. Over the last five days, shares have gained 4.70% and 29.01% year to date. Shares have outperformed the S&P 500 by 15.68% during the last year.

Key company metrics

  • Open(U.S.) $343.28
  • Previous close(U.S.) $353.70
  • High(U.S.) $361.93
  • Low(U.S.) $343.06
  • Bid / Ask-- / --
  • YTD % change+29.01%
  • Volume3,691,331
  • Average volume (10-day)1,817,098
  • Average volume (1-month)2,046,681
  • Average volume (3-month)1,686,445
  • 52-week range(U.S.) $270.62 to (U.S.) $361.93
  • Beta1.10
  • Trailing P/E34.13×
  • P/E 1 year forward26.65×
  • Forward PEG1.22×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $10.57
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+28.09%

Based on its net profit margin of 28.09%, Biogen Idec Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue2,5112,4212,1301,966
Total other revenue--------
Total revenue2,5112,4212,1301,966
Gross profit2,2092,1301,8511,707
Total cost of revenue303292279259
Total operating expense1,3591,4331,4581,309
Selling / general / administrative570577512523
Research & development417447529422
Depreciation / amortization122117143109
Interest expense (income), net operating--------
Unusual expense (income)-540-5-4
Other operating expenses, total0000
Operating income1,153989671657
Interest income (expense), net non-operating-7-7-8-6
Gain (loss) on sale of assets--------
Other--------
Income before tax1,136994666653
Income after tax862725487462
Income tax, total275269178190
Net income857715480457
Total adjustments to net income--------
Net income before extra. items857715480457
Minority interest1-900
Equity in affiliates-5-2-8-5
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items857715480457
Inc. avail. to common incl. extra. items857715480457
Diluted net income857715480457
Dilution adjustment--------
Diluted weighted average shares237237238238
Diluted EPS excluding extraordinary itemsvalue per share3.623.012.021.92
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share3.443.012.001.91